# ARIEL 3 (NCT01968213)

> Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01968213
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: pharmaand GmbH
- Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
- Interventions: Rucaparib; Placebo
- Enrollment: 564
- Primary outcome: Disease Progression According to RECIST Version 1.1, as Assessed by the Investigator, or Death From Any Cause (Investigator Progression Free Survival as Per invPFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 15
- Podcasts: 12

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ariel-3-nct01968213

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01968213", "email": "<work email>"}; the inbox owner confirms by the emailed link.